Business
Exclusivity Period Extension
Exclusivity Period Extension.
About this update from Futura Medical Plc
[{"type":"text","content":"\n Futura Medical PLC\n10 February 2006\n\n\nFor immediate release 10 February 2006\n\n\n\n Futura Medical plc\n\n in final approval process for MED2002\n\nFutura Medical plc (AIM: FUM), the pharmaceutical drug and medical device group\nthat develops innovative products for the sexual healthcare market, announces\nthat the negotiated commercial terms and clinical development program for\nMED2002 are now going through the formal approval process within the major\nglobal pharmaceutical group (MGPG). This process will complete after the expiry\nof the current exclusivity period.\n\nFutura has agreed to extend the exclusivity period to allow the MGPG to complete\nits decision-making process in the near term.\n\nJames Barder, Futura's Chief Executive, said: 'I am delighted to report that we\nare now in the formal approval process within the global pharmaceutical group\nand I look forward to updating shareholders in due course.'\n\nFor further information:\nFutura Medical plc\nJames Barder, Chief Executive Tel: +44 (0) 1483 845 670\nmail to: [email protected] www.futuramedical.co.uk\n\nMedia enquiries:\nBuchanan Communications\nMark Court / Tim Anderson / Rebecca Dietrich Tel: +44 (0) 20 7466 5000\n\n\nNotes to Editors:\n\nFutura Medical plc\n\nFutura Medical is an AIM-listed pharmaceutical drug and medical device group\ndeveloping innovative products for sexual health. The Company is developing a\nportfolio of products with the intention of licensing their manufacture and\ndistribution to major pharmaceutical and healthcare groups. Exclusive\nworldwide distribution agreements have already been signed in respect of\nFutura's two condom safety products, CSD500 and FLD500, with SSL International\nplc, the makers of Durex(TM) condoms.\n\nFutura recently announced the results of pharmacokinetic and pharmacodynamic\nstudies which showed an excellent safety profile and statistically significant\nefficacy on the reformulated gel for erectile dysfunction, MED2003.\n\nFutura's primary focus is on Over the Counter (OTC) products with particular\nappeal to men and women who are reluctant to discuss potentially embarrassing\nsexual matters with their doctors.\n\nIn March 2005 Futura announced it had entered into exclusive discussions until\n31st December 2005 with a major global pharmaceutical group on a proposed\nagreement for the...